Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author holds a long position in CRSP.

← Back to Free Index

CRSP

Analysis as of: 2026-02-05

CRISPR THERAPEUTICS AG

Develops CRISPR/Cas9 gene-edited medicines, with commercial participation in CASGEVY and a wholly-owned in vivo liver-editing pipeline.

biotech healthcare

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • Third Party Analyst Consensus

Summary

Operational throughput unlocks platform re-rating

Upside depends less on “gene editing is real” and more on repeatable delivery economics plus one in vivo liver program becoming underwritable. The next 12–24 months of throughput and safety follow-up largely set the 2031 outcome distribution.

Analysis

Thesis

By 2031, CRSP can shift from “cash + one complex launch” into an underwritable gene-medicine operator: CASGEVY economics scale as treatment throughput clears, while 1 in vivo liver-editing program advances far enough for late-stage/approval-path value; additive outcomes-based contracting + data-rights infrastructure improves durability of value capture.

Last Economy Alignment

AI commoditizes discovery; value concentrates in regulated proof, longitudinal outcomes data, and trusted distribution (payers/centers). CRSP’s IP + clinical learning loops + ability to productize outcomes/data workflows (vs pure “software”) are advantaged in that shift.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

3.8x (from 5 most recent analyses)

Reasoning

CRSP’s re-rate case is operationalization: converting a partner-led launch into repeatable patient flow, and converting in vivo liver-editing into credible late-stage probability. With large net liquidity, the company can fund multiple shots while selectively partnering to pull forward economics and reduce dilution.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The binding risks are (1) operational throughput and reimbursement friction limiting CASGEVY value realization under Vertex control, and (2) multi-year validation of durable safety/efficacy for in vivo editing under regulator/payer standards. If either stays tight, 2031 revenue is materially lower and dilution risk rises.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

No new company-filed clinical datasets surfaced in the last 7–10 days; focus remains on near-term commercial throughput signals.
Near-term repricing is still dominated by upcoming partner disclosure on CASGEVY trajectory (next scheduled event in the pack: Vertex earnings on 2026-02-12).
Street commentary has emphasized in vivo liver-editing optionality, but there has been no new de-risking datapoint since the January 12, 2026 8-K.

Upgrade to Builder to also access: Future Considerations

Third Party Analyst Consensus

12-Month Price Target

$81.33

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case